Literature DB >> 11343624

Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats.

F Borsini1, A Brambilla, R Cesana, N Grippa.   

Abstract

This study was aimed at evaluating the ability of flibanserin, a 5-HT1A receptor full agonist with antidepressant potential, to induce the 5-HT syndrome (flat body posture, hindlimb abduction and forepaw treading) in rats previously administered with clinically active antidepressants imipramine, fluoxetine or paroxetine. The 5-HT syndrome was observed for 50 min after intraperitoneal administration of flibanserin (0, 8 or 64 mg/kg) given 10 min after antidepressants (0 or 15 mg/kg). Flibanserin induced flat body posture and very slight hindlimb abduction only at 64 mg/kg. No dose of flibanserin elicited forepaw treading. Similar but milder symptoms were induced by antidepressants. No interaction between flibanserin and antidepressants was observed. A dose of 10 mg/kg flibanserin did not change the flat body posture induced by 8 mg/kg (+/-)-8-OH-DPAT but antagonized (+/-)-8-OH-DPAT-induced forepaw treading.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343624     DOI: 10.1017/S1461145701002206

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  3 in total

1.  Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality.

Authors:  Yves Aubert; Morgan L Gustison; Lindsey A Gardner; Michael A Bohl; Jason R Lange; Kelly A Allers; Bernd Sommer; Nicole A Datson; David H Abbott
Journal:  J Sex Med       Date:  2012-02-03       Impact factor: 3.802

2.  Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.

Authors:  Clayton English; Anne Muhleisen; Jose A Rey
Journal:  P T       Date:  2017-04

3.  Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.

Authors:  Gongliang Zhang; Swapna Krishnamoorthy; Zhiyuan Ma; Nick P Vukovich; Xupei Huang; Rui Tao
Journal:  Eur J Pharmacol       Date:  2009-05-20       Impact factor: 4.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.